EVX
VanEck Environmental Services ETF
Mentions (24Hr)
-100.00% Today
Reddit Posts
💰💰💰Good morning! #premarket #watchlist 09/22 $SPRO -Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy, $AVCT -4K form , $VRAX -Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.
💰💰💰Good morning! #premarket #watchlist 09/22 $SPRO -Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy, $AVCT -4K form , $VRAX -Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.
Evaxion Biotech’s EVX-01 Personalized Cancer Therapy - $EVAX Stock and Short Update
💰💰💰Good morning! #premarket #watchlist 09/21 $EVAX -Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy, $RMED -Announces Results of its Special Meeting of Stockholders and a 1-for-50 Reverse Stock Split , $WTRH -ASAP Brings its In-Arena Mobile Ordering to the NHL
💰💰💰Good morning! #premarket #watchlist 09/21 $EVAX -Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy, $RMED -Announces Results of its Special Meeting of Stockholders and a 1-for-50 Reverse Stock Split , $WTRH -ASAP Brings its In-Arena Mobile Ordering to the NHL
Evaxion BioTech's $EVAX at $5.75) unique cancer therapy, EVX-01, in development, IMHO, has high potential of becoming a blockbuster
Mentions
Carbon credits, waste-cleaning like WM or the ETF EVX, water-purification-related ETFS, healthcare research, etcetera. However, I suggest not trying to be charitable with your investments, go for whatever gets you the most money, you can be charitable with your gains.
WM Waste management CGW invesco water ETF EVX vaneck environ services ETF CL Colgate DAR darling ingredients So yeah. There’s a theme there. They always bump slightly when the overall market drops
wkhs buying, looking over EV's the EVX is on fire [https://www.tradingview.com/chart/4eOvMnvS/?symbol=SPARKS%3AEVX](https://www.tradingview.com/chart/4eOvMnvS/?symbol=SPARKS%3AEVX)
77 Million shares traded on September 25th and now the cost to borrow shares is 111% according to Fintel. >MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 [https://stockhouse.com/news/press-releases/2025/09/25/evaxion-out-licenses-vaccine-candidate-evx-b3-to-msd](https://stockhouse.com/news/press-releases/2025/09/25/evaxion-out-licenses-vaccine-candidate-evx-b3-to-msd) More than a year without worrying about dilution. I'm in for a year.
EVAX Merck exercises its option on vaccine EVX-B3. Comes with a $7.5 million payment today. Merck will take over all work going forward, but EVAX remains eligible for milestone payments (development, regulatory, and sales milestones) with a total potential value of $592 million PLUS EVAX will receive royalties on sales. Stock closed yesterday at $3.30 (representing a value of $20.8 million). Currently trading at $4.30 in pre-market, representing a valuation of ~$27 million. That is a valuation of $27 million while they stand to receive total payments of $600 million PLUS royalties. NOTE: Check my post history - I suggested this stock in “The Lounge” a couple weeks ago. Good luck to all!
EVAX I don’t understand why EVAX doesn’t get more attention. I STRONGLY encourage folks to take a look, do your diligence, and thank me later. EVAX is an AI-based biotech pharmaceutical company focused on utilizing AI to create new immunology vaccines. They have three vaccines in various stages of trials: EVX-01 (treatment of metastatic melanoma; in phase 2 trials); EVX-02 (DNA-based vaccine to treat respected melanoma; completed phase 1 / 2A trials); EVX-03 (DNA-based vaccine for treatment of various cancers, including non-small cell lung cancer). They also have several pre-clinical stage vaccines in the works. Here is why I like it (in addition to the focus on utilizing AI which I think will be the future of biopharma): MERCK! Merck & Co (NYSE: MRK; one of the largest healthcare and pharmaceutical companies in the world) is their strategic partner and investor. - Merck is an investor through its venture investment vehicle (MSD Global Health Innovation Fund). They purchases shares in two private placements (December 2023 and January 2025). - Merck paid EVAX $3.2 million in September 2024 for options to license two vaccine candidates EVX-B2 and EVX-B3. If Merck chooses to exercise the option, they must pay EVAX another $10 million this year (2025), plus EVAX is entitled to development, regulatory, and sales Milestones totaling up to $592 million PER PRODUCT. Plus, EVAX would receive royalties on sales (in addition to the payments mentioned). EVAX is currently trading at a market cap of $19 million. This is essentially nothing relative to the monies they stand to make from the Merck relationship, not to mention their other vaccine candidates. The stock has been beaten down as most biopharma companies are in between PR announcements and prior to announcements of approvals. It is currently trading around $3.00 per share, down from its 52-week high of $17.20, and up from its 52-week low of $1.20. Disclosure: I am a shareholder. My average basis is $1.78. I initially bought shares in early February 2025 after reading about the relationship with Merck and the fact that Merck had just expressed continued believe via their purchase of more shares in late January 2025). My initial purchases were in the high $3’s and up to $4.09 per share. I then continued to buy throughout the market dip this spring. I hold because I believe this will scream upward on any good news announcements and/or via Merck making the next $10 million option payment. I am not a bag holder. I could sell today and make a 67% profit (nearly $50k of profit).
EVX - has been an amazing performer last 10 years.
it s 2024....we don t say garbage but Environmental Services [Market Summary](https://www.google.com/finance?oq=EVX+etf+&gs_lcrp=EgZjaHJvbWUyDAgAEEUYORiABBiiBDIHCAEQABiABDIICAIQABgWGB4yDQgDEAAYhgMYgAQYigUyDQgEEAAYhgMYgAQYigUyDQgFEAAYhgMYgAQYigUyCggGEAAYgAQYogQyCggHEAAYgAQYogTSAQgzNjE1ajBqMagCALACAA&sourceid=chrome&ie=UTF-8&sa=X&ved=2ahUKEwj46Kj2jLeHAxXt5MkDHci1AjwQ6M8CegQIIhAI) > VanEck Environmental Services ETF173.93 USD+25.84 (17.45%)past 6 months
Garbage are the future. i m long EVX
Electronic waste recycle we got EVX https://www.mainstreetrader.com/otc-tmna1668882273316?gclid=EAIaIQobChMIpMPr2N_T-wIVkDkBCh3ocQWDEAEYASAAEgIPVPD_BwE Chips are still being recycled left and right Trucks Phones All of it Take a look weight be at 9.61
I like EVX. Lots of reasons. It’s comprised of waste management, recycling, haz materials and compliance service providers. I found it a couple of years ago when I looked for some safe and stable long term plays and have been rewarded. Waste handling and environmental services can’t be cut from budgets during downturns.
Hello friends, I have a question... is low trading volume for an ETF a cause for concern? I'm thinking specifically of EVX. I learned about this because I have SMH, another VanEck ETF, in my Roth IRA. I had Ecolab and Waste Management on my watch list and low and behold, those are the top two holdings. However EVX has *very* low volume, like ~2K a day. I understand this would be a warning sign for a single stock, because of the low liquidity. But does that really apply to an ETF? Thank you in advance for your guidance.